Companies / COLL Collegium Pharmaceutical, Inc (COLL)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Ticker COLL Exchange Nasdaq Sector Healthcare Industry Drug Manufacturers - Specialty & Generic Market cap $752.25M 52-week range $21.43 - $50.79 Valuation Share price $24.21 (close of Nov 6, 2026) P/E (TTM) 19.84x Price to book 2.54x Price to free cash flow 2.24x Enterprise value $1.69B Book value per share $9.54 Price performance Period Change 1 day -3.78% 5 days +1.72% 1 month +10.65% 3 months -16.83% 6 months -33.69% Year to date -47.71% 1 year -40.46% 3 years +9.55% 5 years +27.02% 10 years +69.06% All time +96.99%
Short interest As of Oct 15, 2026 Short % of float 19.72% Shares short 5.38M Days to cover 7.17 Change since prior report -2.57% Source FINRA consolidated short interest Profitability and growth Return on equity 20.84% Return on invested capital 13.42% Return on assets 3.79% Return on capital employed 14.76% Gross margin 59.35% Net margin 8.05% EBITDA margin 51.98% Revenue growth 23.62% Net income growth -9.13% Free cash flow growth 61.11% Cash flow and balance sheet Free cash flow yield (TTM) 44.70% Current ratio 1.01x Net debt to EBITDA 2.68x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $780.57M Cost of revenue $317.31M Gross profit $463.26M EBITDA $405.71M Net income $62.87M Earnings per share $1.98 Interest expense $82.31M Shares outstanding 31.71M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 $780.57M $463.26M $62.87M $1.98 2024-12-31 $631.45M $377.34M $69.19M $2.14 2023-12-31 $566.77M $326.17M $48.16M $1.43 2022-12-31 $463.93M $209.49M -$25.00M -$0.74 2021-12-31 $276.87M $150.62M $71.52M $2.05 2020-12-31 $310.02M $179.84M $26.75M $0.78 2019-12-31 $296.70M $103.04M -$22.72M -$0.68 2018-12-31 $280.41M $114.74M -$39.13M -$1.19 2017-12-31 $28.48M $25.88M -$74.86M -$2.47 2016-12-31 $1.71M $1.50M -$94.18M -$3.88
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 59.35% 8.05% 20.84% 13.42% 2024-12-31 59.76% 10.96% 30.23% 12.91% 2023-12-31 57.55% 8.50% 24.64% 16.03% 2022-12-31 45.15% -5.39% -12.83% 3.69% 2021-12-31 54.40% 25.83% 35.24% 5.01% 2020-12-31 58.01% 8.63% 14.38% 18.77% 2019-12-31 34.73% -7.66% -25.99% -21.78% 2018-12-31 40.92% -13.95% -42.72% -20.07% 2017-12-31 90.89% -262.91% -71.93% -72.49% 2016-12-31 87.55% -5,504.15% -69.81% -67.66%
Cash and debt by year Period end Cash Debt 2025-12-31 $231.25M $238.21M 2024-12-31 $70.56M $237.17M 2023-12-31 $238.95M $262.13M 2022-12-31 $173.69M $140.87M 2021-12-31 $186.43M $139.97M 2020-12-31 $174.12M $99.58M 2019-12-31 $170.02M $11.50M 2018-12-31 $146.63M $11.50M 2017-12-31 $118.70M - 2016-12-31 $153.22M $4.15M
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 $327.58M $41.91M 2024-12-31 $203.33M $32.40M 2023-12-31 $274.29M $27.14M 2022-12-31 $122.61M $22.87M 2021-12-31 $101.61M $24.25M 2020-12-31 $88.40M $21.91M 2019-12-31 $21.34M $16.53M 2018-12-31 $163.91M $13.78M 2017-12-31 -$68.01M $7.95M 2016-12-31 -$75.53M $5.79M
Investor relations Past earnings dates Reported Fiscal period EPS estimate 2026-11-05 Sep 2026 $1.53 2026-08-06 Jun 2026 $1.48 2026-05-07 Mar 2026 $1.23 2026-02-26 Dec 2025 $2.01 2025-11-06 Sep 2025 $1.69 2025-08-07 Jun 2025 $1.43 2025-05-08 Mar 2025 $1.29 2025-02-27 Dec 2024 $1.41
Filings and sources Company website collegiumpharma.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Teva Pharmaceutical Industries Ltd (TEVA) · Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades